#1 Clinical Trials Search in Europe

Paracetamol Ph. Eur.

This article explores the use of Paracetamol Ph. Eur. in clinical trials for a range of medical conditions. Paracetamol, also known as acetaminophen, is a common pain reliever and fever reducer. The clinical trials discussed here investigate its potential applications in different therapeutic areas, from cancer to rheumatoid arthritis. These studies aim to assess the safety and efficacy of Paracetamol Ph. Eur. when used alone or in combination with other treatments.

Table of Contents

What is PARACETAMOL PH. EUR.?

PARACETAMOL PH. EUR. is a common pain reliever and fever reducer[1]. It is also known by other names such as acetaminophen or APAP. The “PH. EUR.” in the name stands for “European Pharmacopoeia,” which refers to the official standards for medicine quality in Europe.

This medication belongs to a class of drugs called analgesics (pain relievers) and antipyretics (fever reducers). It works by changing the way your body senses pain and by cooling the body[2].

What is PARACETAMOL PH. EUR. used for?

PARACETAMOL PH. EUR. is commonly used to treat a variety of conditions, including:

  • Mild to moderate pain (such as headaches, toothaches, menstrual cramps, and backaches)
  • Fever reduction
  • Cold and flu symptoms
  • Arthritis pain

In some cases, it may be used in combination with other medications to treat more severe pain or as part of a treatment plan for chronic conditions[3].

How is PARACETAMOL PH. EUR. taken?

The dosage of PARACETAMOL PH. EUR. can vary depending on the specific product and the condition being treated. However, some general guidelines include:

  • For adults: The typical dose is 500-1000 mg every 4-6 hours, not exceeding 4000 mg in 24 hours[4].
  • For children: Dosage is usually based on weight and age. Always follow the instructions provided by your healthcare provider or on the product label.

It’s important to note that PARACETAMOL PH. EUR. can be taken orally in various forms, including tablets, capsules, or liquid formulations. Some formulations may also be administered intravenously in hospital settings[5].

What are the potential side effects?

While PARACETAMOL PH. EUR. is generally considered safe when used as directed, it can cause side effects in some people. Common side effects may include:

  • Nausea
  • Stomach pain
  • Headache
  • Skin rash or itching

In rare cases, more serious side effects can occur, especially with high doses or long-term use. These may include liver damage or allergic reactions. If you experience any unusual symptoms, contact your healthcare provider immediately[6].

Precautions and warnings

While PARACETAMOL PH. EUR. is widely used, there are some important precautions to keep in mind:

  • Liver disease: People with liver problems should use caution and consult their doctor before taking this medication.
  • Alcohol use: Drinking alcohol while taking paracetamol can increase the risk of liver damage.
  • Other medications: Inform your healthcare provider about all medications you’re taking, as paracetamol can interact with certain drugs.
  • Pregnancy and breastfeeding: While generally considered safe, consult your doctor before use if you’re pregnant or breastfeeding.

It’s crucial to follow the recommended dosage and not exceed the maximum daily dose to avoid potential liver damage[7].

Ongoing research

While PARACETAMOL PH. EUR. is a well-established medication, research continues to explore its potential uses and effects. Some ongoing studies are investigating its use in combination with other drugs for various conditions, including:

  • Rheumatoid arthritis: A study is exploring the use of paracetamol alongside other medications for patients with active rheumatoid arthritis[7].
  • Cancer-related pain: Research is being conducted on the use of paracetamol as part of pain management strategies in cancer patients[4].
  • Cardiovascular conditions: Some studies are investigating the potential role of paracetamol in patients with certain heart conditions[3].

These ongoing studies may provide new insights into the potential benefits and applications of PARACETAMOL PH. EUR. in various medical contexts.

Aspect Details
Medical Conditions Studied Multiple myeloma, chronic pain due to diabetic polyneuropathy, acute myocardial infarction, mantle cell lymphoma, Hodgkin and non-Hodgkin lymphoma, rheumatoid arthritis
Administration Routes Oral, intravenous, and other routes as specified by individual trials
Dosage Range Varies by trial, from 500 mg to 4000 mg daily
Trial Durations Range from a few weeks to over 52 weeks
Primary Objectives Evaluate safety, efficacy, pharmacokinetics, and combination therapy potential
Key Endpoints Pain reduction, disease progression, quality of life improvements, adverse event monitoring
Patient Demographics Adults (typically 18 years and older), with specific age ranges varying by study
Combination Therapies Used alone or in combination with other drugs such as rituximab, certolizumab, and various cancer therapies

FAQ

  • What medical conditions are being studied with Paracetamol Ph. Eur. in these clinical trials? The clinical trials are investigating Paracetamol Ph. Eur. in various conditions including multiple myeloma, chronic pain due to diabetic polyneuropathy, acute myocardial infarction, mantle cell lymphoma, Hodgkin and non-Hodgkin lymphoma, and rheumatoid arthritis.
  • How is Paracetamol Ph. Eur. administered in these studies? The administration of Paracetamol Ph. Eur. varies across studies. It may be given orally, intravenously, or through other routes depending on the specific trial design and medical condition being treated.
  • What are the main objectives of these clinical trials? The main objectives include evaluating the safety and efficacy of Paracetamol Ph. Eur., assessing its pharmacokinetics (how the body processes the drug), and determining its effectiveness when used alone or in combination with other treatments for various medical conditions.
  • Are there any specific side effects being monitored in these trials? While specific side effects may vary by trial, researchers generally monitor for adverse events related to Paracetamol Ph. Eur. use. This can include changes in liver function, allergic reactions, and any unexpected side effects that may occur during the study period.
  • How long do these clinical trials typically last? The duration of the clinical trials varies widely, ranging from a few weeks to several months or even years. For example, some studies last 12 weeks, while others may continue for up to 52 weeks or longer, depending on the research objectives and the condition being studied.

Ongoing Clinical Trials on Paracetamol Ph. Eur.

  • Study on the Effectiveness and Safety of Dapirolizumab Pegol for Patients with Moderate to Severe Systemic Lupus Erythematosus

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Denmark France Germany Greece Italy +3

  • Study on the Long-Term Safety of Dapirolizumab Pegol for Patients with Systemic Lupus Erythematosus

    Recruiting

    3 1 1 1
    Investigated drugs:
    Belgium Bulgaria Czechia Denmark France Germany +7

  • Study of Axicabtagene Ciloleucel for Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Nipocalimab and Certolizumab for Patients with Active Rheumatoid Arthritis After Advanced Therapy

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Hungary Poland

  • Study on the Safety and Effectiveness of GEN3017 for Patients with Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Denmark France Germany Italy The Netherlands

  • Study on [68Ga]Ga-PentixaFor for Detecting Multiple Myeloma in Patients Under 66 Eligible for Stem Cell Transplantation

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Effectiveness and Safety of AP707, Amitriptyline, and Capsaicin for Patients with Chronic Pain from Diabetic Neuropathy

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Germany

  • Study on the Safety and Effectiveness of SKB264 and Pembrolizumab for Patients with Cervical, Urothelial, Ovarian, or Prostate Cancer

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Poland Spain

Glossary

  • Paracetamol Ph. Eur.: A pharmaceutical grade of paracetamol (acetaminophen) that meets the standards set by the European Pharmacopoeia. It is a pain reliever and fever reducer used in various medical treatments.
  • Clinical Trial: A research study that tests how well new medical approaches work in people. These studies test new methods of screening, prevention, diagnosis, or treatment of a disease.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Adverse Event: Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure.
  • Efficacy: The ability of a drug or medical treatment to produce a desired effect or result in treating a disease or condition.
  • Rheumatoid Arthritis (RA): A chronic inflammatory disorder affecting many joints, including those in the hands and feet. It causes pain, swelling, and stiffness in the joints.
  • Multiple Myeloma: A cancer that forms in a type of white blood cell called a plasma cell. These cancerous plasma cells accumulate in the bone marrow and crowd out healthy blood cells.
  • Lymphoma: A type of cancer that begins in cells of the lymph system, which is part of the body's immune system.
  • Myocardial Infarction: Commonly known as a heart attack, it occurs when blood flow to the heart is blocked, causing damage to the heart muscle.
  • Diabetic Polyneuropathy: A type of nerve damage that can occur in people with diabetes. It most often affects the nerves in the feet and legs.

References

  1. http://clinicaltrials.eu/trial/study-on-68gaga-pentixafor-for-detecting-multiple-myeloma-in-patients-under-66-eligible-for-stem-cell-transplantation/
  2. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-ap707-amitriptyline-and-capsaicin-for-patients-with-chronic-pain-from-diabetic-neuropathy/
  3. http://clinicaltrials.eu/trial/study-on-rituximab-for-patients-with-acute-myocardial-infarction/
  4. http://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-skb264-and-pembrolizumab-for-patients-with-cervical-urothelial-ovarian-or-prostate-cancer/
  5. http://clinicaltrials.eu/trial/study-comparing-glofitamab-alone-to-bendamustine-with-rituximab-or-lenalidomide-with-rituximab-for-patients-with-relapsed-or-refractory-mantle-cell-lymphoma/
  6. http://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-gen3017-for-patients-with-relapsed-or-refractory-hodgkin-and-non-hodgkin-lymphoma/
  7. http://clinicaltrials.eu/trial/study-on-nipocalimab-and-certolizumab-for-patients-with-active-rheumatoid-arthritis-after-advanced-therapy/